3,4,5-Trimethoxyamphetamine

3,4,5-Trimethoxyamphetamine (TMA) is a psychedelic drug and a substituted amphetamine. It is known for its hallucinogenic effects, which are similar to those of other psychedelic drugs like LSD and mescaline.

History

TMA was first synthesized by the chemist Alexander Shulgin in the 1960s. Shulgin described the effects of TMA in his book PiHKAL, where he reported that the drug produces a "gentle and stately" psychedelic experience.

Pharmacology

TMA acts as a serotonin receptor agonist. It binds to and activates the serotonin receptors in the brain, which leads to the release of serotonin, a neurotransmitter that plays a key role in regulating mood, appetite, and sleep.

Effects

The effects of TMA can vary greatly depending on the dose, the individual's body chemistry, and the environment in which it's taken. Common effects include visual hallucinations, enhanced sensory perception, and altered thought patterns. Some users also report experiencing a sense of euphoria and increased empathy.

Risks

Like all psychedelic drugs, TMA carries risks. These can include psychological distress, such as anxiety and paranoia, as well as physical risks like increased heart rate and blood pressure. There is also the risk of having a "bad trip," which can be a highly distressing and potentially traumatic experience.

Legal status

TMA is classified as a Schedule I drug in the United States, meaning it is illegal to manufacture, distribute, or possess. It is also illegal in many other countries, including the United Kingdom and Australia.

See also

• Psychedelic drug
• Substituted amphetamine
• Alexander Shulgin
• PiHKAL
• Serotonin receptor
• Schedule I drug